Stocks · News reference
GeneDx Advances Clinical Adoption Of Genomic Medicine With 27 Abstracts At American Society Of Human Genetics 2026
Research strengthens the evidence for exome and genome sequencing as standard of care across rare disease, autism, newborn screening and beyond
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Groupon Posts Downbeat Q3 Results, Joins GeneDx Holdings, Qualys And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Groupon plunged 20% premarket after missing quarterly earnings and sales estimates, while Digital Turbine, Daqo and others also traded lower.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Co-Diagnostics (NASDAQ:CODX) stock moved upwards by 22.4% to $0.39 during Tuesday's pre-market session. The company's market cap stands at $2.8 million. As per the press release, Q3 earnings came out
GeneDx Holdings Q3 2026 Earnings Call Transcript
GeneDx Holdings (NASDAQ:WGS) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs.
GeneDx Holdings Corp. Reports Q3 2026 Financial Results
GeneDx Holdings Corp. announced its third-quarter 2026 financial results, reporting revenue of $123.1 million and adjusted earnings per share of $0.28.
GeneDx Holdings Affirms FY2026 Sales Guidance of $475.000M-$490.000M vs $482.324M Est